Did you know, Dymista® provides a 30 minute onset of action in clinical practice, with efficacy confirmed in real life
Dymista® provides a 30 minute onset of action in clinical practice1
Click below to hear from the experts about the 30 minute onset of action and real-life results
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
Impact of Rhinitis
- Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasonepropionate) in the treatment of seasonal allergic rhinitis: a randomized, double- blind. Placebo-controlled trial of efficacy and safety. Allergy AsthmaProc. 2012; 33: 324-332.
- Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, el al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real—life: Results from a noninterventional study. Allergy AsthmaProc. 2015; 36: 40-47.